Welcome to our dedicated page for Rigel Pharmaceuticals news (Ticker: RIGL), a resource for investors and traders seeking the latest updates and insights on Rigel Pharmaceuticals stock.
Rigel Pharmaceuticals reports news on a commercial-stage biotechnology business focused on hematologic disorders and cancer. Company updates commonly cover sales of TAVALISSE (fostamatinib disodium hexahydrate), GAVRETO (pralsetinib) and REZLIDHIA (olutasidenib), along with contract revenue from collaborations and quarterly operating results.
Recurring developments also include clinical and regulatory updates for Rigel's pipeline, including R289 in lower-risk MDS, published clinical data involving GAVRETO, licensing and collaboration activity, board appointments, equity inducement grants and other governance matters tied to its Nasdaq-listed common stock.
Rigel Pharmaceuticals announced an investigator-sponsored trial (IST) by Imperial College London to assess the efficacy of fostamatinib, an oral SYK inhibitor, for treating COVID-19 pneumonia. Fostamatinib, marketed as TAVALISSE in the U.S., is FDA-approved for chronic immune thrombocytopenia. The trial aims to determine its effectiveness compared to ruxolitinib and standard care in preventing severe COVID-19 pneumonia. Initial studies suggest fostamatinib may inhibit inflammatory processes involved in the disease, providing hope for patients experiencing acute respiratory distress syndrome.